{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:41:37Z","timestamp":1789872097925,"version":"4.0.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,3]],"date-time":"2013-07-03T00:00:00Z","timestamp":1372809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.vaccine.2013.06.079","type":"journal-article","created":{"date-parts":[[2013,7,27]],"date-time":"2013-07-27T00:53:45Z","timestamp":1374886425000},"page":"4501-4507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["Identifying protective dengue vaccines: Guide to mastering an empirical process"],"prefix":"10.1016","volume":"31","author":[{"given":"Scott B.","family":"Halstead","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vaccine.2013.06.079_bib0005","doi-asserted-by":"crossref","first-page":"674","DOI":"10.4161\/hv.7.6.14985","article-title":"Vaccines for the prevention of dengue: development update","volume":"7","author":"Thomas","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0010","first-page":"129","article-title":"Dengue vaccine candidates in development","volume":"338","author":"Durbin","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2013.06.079_bib0015","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.3390\/v3101800","article-title":"Next-generation dengue vaccines: novel strategies currently under development","volume":"3","author":"Durbin","year":"2011","journal-title":"Viruses"},{"issue":"42","key":"10.1016\/j.vaccine.2013.06.079_bib0020","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1016\/j.vaccine.2011.06.094","article-title":"From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine","volume":"29","author":"Guy","year":"2011","journal-title":"Vaccine"},{"issue":"42","key":"10.1016\/j.vaccine.2013.06.079_bib0025","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.1016\/j.vaccine.2011.07.017","article-title":"Next generation dengue vaccines: a review of candidates in preclinical development","volume":"29","author":"Schmitz","year":"2011","journal-title":"Vaccine"},{"issue":"42","key":"10.1016\/j.vaccine.2013.06.079_bib0030","doi-asserted-by":"crossref","first-page":"7267","DOI":"10.1016\/j.vaccine.2011.07.021","article-title":"The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease","volume":"29","author":"Coller","year":"2011","journal-title":"Vaccine"},{"issue":"42","key":"10.1016\/j.vaccine.2013.06.079_bib0035","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1016\/j.vaccine.2011.07.020","article-title":"Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever","volume":"29","author":"Osorio","year":"2011","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2013.06.079_bib0040","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/infdis\/jis936","article-title":"A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial","volume":"207","author":"Durbin","year":"2013","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2013.06.079_bib0045","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4269\/ajtmh.2008.78.426","article-title":"Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children","volume":"78","author":"Simasathien","year":"2008","journal-title":"Am J Trop Med Hyg"},{"issue":"9853","key":"10.1016\/j.vaccine.2013.06.079_bib0050","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"issue":"9853","key":"10.1016\/j.vaccine.2013.06.079_bib0055","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(12)61510-4","article-title":"Dengue vaccine development: a 75% solution?","volume":"380","author":"Halstead","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.vaccine.2013.06.079_bib0060","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.4049\/jimmunol.0801974","article-title":"A protective role for dengue virus-specific CD8+ T cells","volume":"182","author":"Yauch","year":"2009","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2013.06.079_bib0065","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1017\/S0022172400007476","article-title":"Further Experiments in the Etiology of Dengue Fever","volume":"18","author":"Cleland","year":"1919","journal-title":"J Hyg (Lond)"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0070","first-page":"1","article-title":"St John JH, Reynolds FHK. Experimental studies of dengue","volume":"44","author":"Simmons","year":"1931","journal-title":"Philipp J Sci"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0075","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1126\/science.101.2634.640","article-title":"Production of immunity to dengue with virus modified by propagation in mice","volume":"101","author":"Sabin","year":"1945","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0080","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4269\/ajtmh.1952.1.30","article-title":"Research on dengue during World War II","volume":"1","author":"Sabin","year":"1952","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"10.1016\/j.vaccine.2013.06.079_bib0085","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1128\/JVI.73.1.783-786.1999","article-title":"New mouse model for dengue virus vaccine testing","volume":"73","author":"Johnson","year":"1999","journal-title":"J Virol"},{"issue":"21","key":"10.1016\/j.vaccine.2013.06.079_bib0090","doi-asserted-by":"crossref","first-page":"11436","DOI":"10.1128\/JVI.77.21.11436-11447.2003","article-title":"Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development","volume":"77","author":"Huang","year":"2003","journal-title":"J Virol"},{"issue":"1-2","key":"10.1016\/j.vaccine.2013.06.079_bib0095","first-page":"1","article-title":"Experimental Studies of Dengue","volume":"44","author":"Simmons","year":"1931","journal-title":"Philip J Sci"},{"issue":"2","key":"10.1016\/j.vaccine.2013.06.079_bib0100","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1006\/viro.1998.9200","article-title":"Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica","volume":"246","author":"Roehrig","year":"1998","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2013.06.079_bib0105","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4269\/ajtmh.1970.19.94","article-title":"Sequential dengue virus infections in the white-handed gibbon (hylobates lar)","volume":"19","author":"Whitehead","year":"1970","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"10.1016\/j.vaccine.2013.06.079_bib0110","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4269\/ajtmh.1973.22.365","article-title":"Studies on the immunization of monkeys against dengue. 1. protection derived from single and sequential virus infections","volume":"22","author":"Halstead","year":"1973","journal-title":"Am J Trop Med Hyg"},{"issue":"35","key":"10.1016\/j.vaccine.2013.06.079_bib0115","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1016\/j.vaccine.2005.03.042","article-title":"An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model","volume":"23","author":"Putnak","year":"2005","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2013.06.079_bib0120","doi-asserted-by":"crossref","first-page":"e1267","DOI":"10.1371\/journal.pntd.0001267","article-title":"A Single Dose of the DENV-1 Candidate Vaccine rDEN1Delta30 Is Strongly Immunogenic and Induces Resistance to a Second Dose in a Randomized Trial","volume":"5","author":"Durbin","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2013.06.079_bib0125","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.humimm.2012.07.328","article-title":"Impact of infection or vaccination on pre-existing serological memory","volume":"73","author":"Amanna","year":"2012","journal-title":"Hum Immunol"},{"issue":"19","key":"10.1016\/j.vaccine.2013.06.079_bib0130","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1073\/pnas.1200566109","article-title":"Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions","volume":"109","author":"de Alwis","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"139","key":"10.1016\/j.vaccine.2013.06.079_bib0135","doi-asserted-by":"crossref","first-page":"139ra83","DOI":"10.1126\/scitranslmed.3003888","article-title":"The structural basis for serotype-specific neutralization of dengue virus by a human antibody","volume":"4","author":"Teoh","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0140","first-page":"93","article-title":"Report of dengue vaccine trial in the Caribbean, 1963: a collaborative study","volume":"35","author":"Bellanti","year":"1966","journal-title":"Bull WHO"},{"issue":"9188","key":"10.1016\/j.vaccine.2013.06.079_bib0145","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0140-6736(99)04015-5","article-title":"Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever","volume":"354","author":"Watts","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0150","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0140-6736(02)09522-3","article-title":"Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever","volume":"360","author":"Kochel","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0155","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1086\/427511","article-title":"Cross-serotype neutralization of dengue virus in Aotus nancymae monkeys","volume":"191","author":"Kochel","year":"2005","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2013.06.079_bib0160","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1590\/S1020-49892002000400003","article-title":"Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks","volume":"11","author":"Guzman","year":"2002","journal-title":"Rev Panam Salud Publica"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0165","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3201\/eid1302.060539","article-title":"Neutralizing antibodies after infection with dengue 1 virus","volume":"13","author":"Guzman","year":"2007","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2013.06.079_bib0170","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.virol.2008.08.008","article-title":"Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model","volume":"380","author":"Kyle","year":"2008","journal-title":"Virology"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2013.06.079_bib0175","first-page":"E12","article-title":"A mouse model for studying dengue virus pathogenesis and immune response","volume":"1171","author":"Williams","year":"2009","journal-title":"Ann NY Acad Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2013.06.079_bib0180","doi-asserted-by":"crossref","first-page":"404","DOI":"10.4049\/jimmunol.1102124","article-title":"Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells","volume":"188","author":"Zompi","year":"2012","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2013.06.079_bib0185","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.4049\/jimmunol.1101970","article-title":"Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design","volume":"187","author":"Weiskopf","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0190","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1305227110","article-title":"Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells","author":"Weiskopf","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.vaccine.2013.06.079_bib0195","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4269\/ajtmh.1989.40.444","article-title":"Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever","volume":"40","author":"Kliks","year":"1989","journal-title":"Am J Trop Med Hyg"},{"issue":"9872","key":"10.1016\/j.vaccine.2013.06.079_bib0200","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(13)60754-0","article-title":"Efficacy of tetravalent dengue vaccine in Thai schoolchildren","volume":"381","author":"Moi","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0205","first-page":"350","article-title":"Observations related to pathogenesis of dengue hemorrhagic fever VI. hypotheses and discussion","volume":"42","author":"Halstead","year":"1970","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0210","first-page":"329","article-title":"Observations related to pathogenesis of dengue hemorrhagic fever. V. Examination of age specific sequential infection rates using a mathematical model","volume":"42","author":"Fischer","year":"1970","journal-title":"Yale J Biol Med"},{"issue":"5","key":"10.1016\/j.vaccine.2013.06.079_bib0215","doi-asserted-by":"crossref","first-page":"910","DOI":"10.4269\/ajtmh.2007.77.910","article-title":"Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences","volume":"77","author":"Gibbons","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0220","first-page":"103","article-title":"Antibody response in dengue and dengue hemorrhagic fever","volume":"20","author":"Russell","year":"1967","journal-title":"Jpn J Med Sci Biol"},{"issue":"3","key":"10.1016\/j.vaccine.2013.06.079_bib0225","doi-asserted-by":"crossref","first-page":"e1568","DOI":"10.1371\/journal.pntd.0001568","article-title":"Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans","volume":"6","author":"Zompi","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2013.06.079_bib0230","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4269\/ajtmh.2009.80.302","article-title":"Evaluation of interferences between dengue vaccine serotypes in a monkey model","volume":"80","author":"Guy","year":"2009","journal-title":"Am J Trop Med Hyg"},{"issue":"9","key":"10.1016\/j.vaccine.2013.06.079_bib0235","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.vaccine.2005.09.029","article-title":"Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults","volume":"24","author":"Kitchener","year":"2006","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2013.06.079_bib0240","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4161\/hv.5.1.6348","article-title":"Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults","volume":"5","author":"Sun","year":"2009","journal-title":"Hum Vaccin"},{"issue":"3","key":"10.1016\/j.vaccine.2013.06.079_bib0245","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/infdis\/jir279","article-title":"Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate","volume":"204","author":"Anderson","year":"2011","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2013.06.079_bib0250","doi-asserted-by":"crossref","first-page":"978","DOI":"10.4269\/ajtmh.2011.10-0592","article-title":"Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques","volume":"84","author":"Osorio","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0255","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1006\/viro.2002.1462","article-title":"Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates","volume":"298","author":"Guirakhoo","year":"2002","journal-title":"Virology"},{"issue":"9","key":"10.1016\/j.vaccine.2013.06.079_bib0260","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1128\/JVI.78.9.4761-4775.2004","article-title":"Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates","volume":"78","author":"Guirakhoo","year":"2004","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2013.06.079_bib0265","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/649916","article-title":"A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults","volume":"201","author":"Morrison","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0270","series-title":"Vaccines","first-page":"385","article-title":"Polio Vaccine-Live","author":"Sutter","year":"2008"},{"issue":"12","key":"10.1016\/j.vaccine.2013.06.079_bib0275","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1128\/JVI.74.12.5477-5485.2000","article-title":"Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman Primates","volume":"74","author":"Guirakhoo","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0280","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/hv.2.2.2555","article-title":"Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes","volume":"2","author":"Guirakhoo","year":"2006","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0285","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1086\/382280","article-title":"The relationship of pre-existing dengue virus neutralizing antibody levels to viremia and disease severity in a prospective cohort study of dengue in Thailand","volume":"189","author":"Endy","year":"2004","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2013.06.079_bib0290","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/infdis\/jis749","article-title":"The dengue human challenge model: has the time come to accept this challenge?","volume":"207","author":"Durbin","year":"2013","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2013.06.079_bib0295","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/infdis\/jis744","article-title":"Experimental Dengue Virus Challenge of Human Subjects Previously Vaccinated With Live Attenuated Tetravalent Dengue Vaccines","volume":"207","author":"Sun","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0300","series-title":"Dengue and dengue hemorrhagic fever","first-page":"367","article-title":"Live attenuated tetravalent dengue vaccine","author":"Bhamarapravati","year":"1997"},{"issue":"23","key":"10.1016\/j.vaccine.2013.06.079_bib0305","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1016\/j.vaccine.2006.03.066","article-title":"Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3)","volume":"24","author":"Sanchez","year":"2006","journal-title":"Vaccine"},{"issue":"6 Suppl","key":"10.1016\/j.vaccine.2013.06.079_bib0310","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4269\/ajtmh.2003.69.6_suppl.0690024","article-title":"Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates","volume":"69","author":"Sun","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0315","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.inf.0000109289.55856.27","article-title":"Safety and immunogenicity of two tetravalent live attenuated dengue vaccines in 5-12 year old Thai children","volume":"23","author":"Sabchareon","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2013.06.079_bib0320","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ni.1688","article-title":"Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans","volume":"10","author":"Querec","year":"2009","journal-title":"Nat Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2013.06.079_bib0325","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/icb.2010.155","article-title":"Insights into human CD8(+) T-cell memory using the yellow fever and smallpox vaccines","volume":"89","author":"Ahmed","year":"2011","journal-title":"Immunol Cell Biol"},{"issue":"9","key":"10.1016\/j.vaccine.2013.06.079_bib0330","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.4049\/jimmunol.1001709","article-title":"CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination","volume":"185","author":"Yauch","year":"2010","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2013.06.079_bib0335","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/cid\/cis655","article-title":"Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial","volume":"55","author":"Tam","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2013.06.079_bib0340","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/cis1047","article-title":"Dengue vascular permeability syndrome: what no T cells?","volume":"56","author":"Halstead","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0345","doi-asserted-by":"crossref","first-page":"838","DOI":"10.4049\/jimmunol.105.4.838","article-title":"Immunoprecipitation analysis of soluble complement-fixing antigens of dengue viruses","volume":"105","author":"Russell","year":"1970","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0350","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1086\/500949","article-title":"Vascular leakage in severe dengue virus infections: A potential role for the nonstructural viral protein NS1 and complement","volume":"193","author":"Avirutnan","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0355","first-page":"117","article-title":"Pathogenic mechanisms in dengue hemorrhagic fever. Report of an international collaborative study","volume":"48","author":"Memoranda","year":"1973","journal-title":"Bull WHO"},{"issue":"3","key":"10.1016\/j.vaccine.2013.06.079_bib0360","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jinf.2011.11.023","article-title":"Dengue virus nonstructural protein NS1 binds to prothrombin\/thrombin and inhibits prothrombin activation","volume":"64","author":"Lin","year":"2012","journal-title":"J Infect"},{"issue":"4","key":"10.1016\/j.vaccine.2013.06.079_bib0365","doi-asserted-by":"crossref","first-page":"638","DOI":"10.4269\/ajtmh.2009.08-0008","article-title":"Hemostatic changes in Vietnamese children with mild dengue correlate with the severity of vascular leakage rather than bleeding","volume":"81","author":"Wills","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0370","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1099\/0022-1317-68-3-853","article-title":"Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1","volume":"68","author":"Schlesinger","year":"1987","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0375","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1006\/viro.1993.1015","article-title":"The Fc portion of antibody to yellow fever virus-ns1 is a determinant of protection against YF encephalitis in mice","volume":"192","author":"Schlesinger","year":"1993","journal-title":"Virology"},{"issue":"4","key":"10.1016\/j.vaccine.2013.06.079_bib0380","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.4049\/jimmunol.135.4.2805","article-title":"Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48","volume":"135","author":"Schlesinger","year":"1985","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2013.06.079_bib0385","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1128\/jvi.60.3.1153-1155.1986","article-title":"Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1","volume":"60","author":"Schlesinger","year":"1986","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2013.06.079_bib0390","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1099\/0022-1317-69-8-2101","article-title":"Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus","volume":"69","author":"Henchal","year":"1988","journal-title":"J Gen Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2013.06.079_bib0395","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1128\/jvi.64.9.4356-4363.1990","article-title":"Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis","volume":"64","author":"Falgout","year":"1990","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2013.06.079_bib0400","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/infdis\/jit273","article-title":"Reduced risk of disease during postsecondary dengue virus infections","volume":"208","author":"Olkowski","year":"2013","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1300889X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1300889X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T15:37:08Z","timestamp":1731339428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1300889X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":80,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0264410X1300889X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.06.079","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying protective dengue vaccines: Guide to mastering an empirical process","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.06.079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}